An Open-label Study to Investigate the Influence of Nurandociguat on the Pharmacokinetics of Rosuvastatin and Dabigatran in Healthy Participants
Latest Information Update: 15 May 2026
At a glance
- Drugs Nurandociguat (Primary) ; Dabigatran etexilate; Rosuvastatin
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 12 May 2026 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Apr 2026 New trial record